EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

CORTICOSTEROIDS IN STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: A REVIEW OF RECENT CLINICAL EVIDENCE

Dinda Salsabila Putri, Sylvia Anggraeni

Magna Scientia Advanced Research and Reviews · 01.11.2026 · 18 (2) · 073

DOI: 10.30574/msarr.2026.18.2.0211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Magna Scientia Advanced Research and Reviews, online erschienen am 01.11.2026. Verfasst von Dinda Salsabila Putri und 1 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening mucocutaneous reactions with high mortality. The role of systemic corticosteroids remains controversial. This review summarizes recent clinical evidence on their use in SJS and TEN.

Methods

PubMed was searched for English-language clinical studies published between 1 January 2015 and 31 December 2025 using the terms "Stevens–Johnson syndrome" or "toxic epidermal necrolysis" combined with "corticosteroids" or "systemic corticosteroid therapy." Eight relevant studies (one systematic review and meta-analysis and seven retrospective studies) were included. Study design, corticosteroid regimens, outcomes, and adverse events were extracted and summarized descriptively.

Results

The meta-analysis of 96 studies (3,248 patients) found a survival benefit with corticosteroids in all analyses, significant in only one. Several single-center cohorts from China reported mortality significantly lower than that predicted by the SCORTEN severity score. In contrast, a Japanese nationwide cohort of 1,846 patients found no significant association between early corticosteroid therapy and lower in-hospital mortality, and a US multicenter cohort showed lower-than-predicted mortality in all groups, including supportive care alone. Adding intravenous immunoglobulin showed a favorable but non-significant trend. Corticosteroid-related complications were mostly mild where reported.

Conclusion

Evidence on corticosteroids in SJS/TEN is inconclusive, limited by retrospective designs, small samples, and heterogeneous dosing. Corticosteroids may be reasonable in selected patients but are not a proven standard treatment. Prospective multicenter studies and randomized trials are needed.

Zitieren

APA

Putri, D. S., & Anggraeni, S. (2026). CORTICOSTEROIDS IN STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: A REVIEW OF RECENT CLINICAL EVIDENCE. Magna Scientia Advanced Research and Reviews, 18(2), 073. https://doi.org/10.30574/msarr.2026.18.2.0211

Vancouver

Putri DS, Anggraeni S. CORTICOSTEROIDS IN STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: A REVIEW OF RECENT CLINICAL EVIDENCE. Magna Scientia Advanced Research and Reviews. 2026;18(2):073. doi:10.30574/msarr.2026.18.2.0211

BibTeX
@article{Putri2026,
  author = {Putri, Dinda Salsabila and Anggraeni, Sylvia},
  title = {CORTICOSTEROIDS IN STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: A REVIEW OF RECENT CLINICAL EVIDENCE},
  journal = {Magna Scientia Advanced Research and Reviews},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {073},
  doi = {10.30574/msarr.2026.18.2.0211}
}
Kostenlos starten →